Clinical trials: Invasive Aspergillosis
Aspergillosis, Candidiasis
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
The objective of this study is to evaluate the efficacy, safety and toleration of voriconazole in the primary treatment of systemic or invasive fungal infections due to fungal pathogens for which there is no licensed therapy; and…
- Conditions
- Aspergillosis, Candidiasis, Fungemia, Mycoses
- Trial name
- NCT00001810
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Focus: Immunocompromised Individuals at High Risk of Aqcuiring Invasive Aspergillosis
Diagnostic Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples
Multicentre, diagnostic study evaluating the performance of an aspergillus-specific PCR in cerebrospinal fluid samples of immunocompromised patients for identification of central nervous system aspergillosis.
- Trial name
- NCT01614145
- Where
- 3 sites in Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Aspergillosis
To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early
Chemotherapy lowers the white blood cell count or weakens the immune system for a long time. This puts the patients at a high risk of getting a serious fungal infection of the internal organs or blood.
- Trial name
- NCT00361517
- Testing
- Galactomannan antigen monitoring, Aspergillus PCR, blood draws, blood draws for GM monitoring
- Where
- Singapore
- Volunteers
- 47 people
- Sponsor
- Singapore General Hospital
Candidiasis, Esophageal, Candidiasis, Invasive
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.
- Conditions
- Candidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis
- Trial name
- NCT01165320
- Testing
- Caspofungin
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematological Diseases, Invasive Aspergillosis
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Evaluation of incidence of invasive aspergillosis in patients who have undergone an allogeneic stem cell transplantation, with particular regard to the role of galactomannan assay and of early TC scan in asymptomatic patients.
- Trial name
- NCT00838643
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Aspergillosis/Blood, Aspergillosis/Invasive
A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis
To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis.
- Trial name
- NCT00423163
- Testing
- micafungin, voriconazole
- Where
- 44 sites in United States
- Sponsor
- Astellas Pharma Inc
Invasive Aspergillosis
Incidence of Invasive Aspergillosis and Its Relation to Galactomannan Clinical Outcomes
The goal of this observational study is to analyze the relationship between galactomannan index values and clinical outcomes , as well as to determine the annual and seasonal incidence of invasive aspergillosis in pediatric and…
- Trial name
- NCT07621263
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Hospital H+ Queretaro
Acute Myeloid Leukemia, Aspergillosis
Pre-hospital Risk Factors for Invasive Fungal Infection
SEIFEM 2010 study is a prospective, multicenter registry designed to identify and analyze risk factors for developing an invasive fungal infection in patients with newly diagnosed Acute Myeloid Leukemia, with particular interest…
- Conditions
- Acute Myeloid Leukemia, Aspergillosis, Candidiasis, Mycoses
- Trial name
- SEIFEM 2010 (NCT01315925)
- Where
- 42 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Catholic University of the Sacred Heart
Pulmonary Aspergillosis
Azole-resistance in Aspergillus
Prospective multi-center surveillance study on the prevalence of azole-resistant Aspergillus spp. in clinical isolates of patients with pulmonary colonization or invasive infections in Switzerland
- Trial name
- NCT03443336
- Where
- Switzerland
- Volunteers
- 400 people
- Sponsor
- University Hospital, Basel, Switzerland
Fever, Mycoses
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
The objective of this study is to evaluate the safety, tolerance, and pharmacokinetics of FK463, a novel echinocandin (cell wall-active antifungal lipopeptide), as early empirical therapy for prevention of fungal infections in…
- Conditions
- Fever, Mycoses, Neutropenia
- Trial name
- NCT00001790
- Testing
- FK463
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Infection, Invasive Fungal
Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)
This retrospective study is designed to provide a consistent method of screening and collecting data on patients who will serve as controls for a comparison of the efficacy of the available antifungal therapies used as salvage…
- Trial name
- NCT00230243
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)
Invasive aspergillosis is a type of fungal infection typically identified in very sick patients (for example, patients with cancer or who have had a bone marrow or organ transplant).
- Trial name
- NCT00076869
- Testing
- MK0991, caspofungin acetate, Comparator: amphotericin B, Comparator: lipid formulation of amphotericin B and/or azole
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Acquired Immunodeficiency Syndrome, Aspergillosis
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
Invasive aspergillosis is a fungal disease which is increasing in incidence with the increase in immunocompromised persons in our population.
- Conditions
- Acquired Immunodeficiency Syndrome, Aspergillosis, HIV Infections, Immunologic Deficiency Syndromes
- Trial name
- NCT00001646
- Testing
- Voriconazole, Amphotericin B
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Pulmonary Aspergillosis, Lymphoblastic Leukaemia
Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
The trial evaluates the overall tolerability of the drug and the efficacy of aerosolised amphotericin B as a lipid complex (ABLC) for primary prophylaxis of invasive pulmonary aspergillosis (IPA) in pediatric patients with acute…
- Conditions
- Invasive Pulmonary Aspergillosis, Lymphoblastic Leukaemia, Myeloblastic Leukaemia, Lymphoblastic Leukemia
- Trial name
- NCT01615809
- Testing
- AMPHOTERICIN B
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- Fundació Sant Joan de Déu
Invasive Aspergillosis
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.
- Trial name
- NCT00836875
- Testing
- Voriconazole
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Infection, Pulmonary Complications
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
RATIONALE: Antifungal therapy with voriconazole or amphotericin B may be an effective treatment for aspergillosis. It is not yet known whether voriconazole is more effective than amphotericin B in treating patients with…
- Trial name
- NCT00003031
- Testing
- amphotericin B deoxycholate, voriconazole
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 212 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Invasive Aspergillosis, Other Fungal Infections
Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment
To evaluate and compare two AmBisome dosing regimens for the initial treatment of invasive aspergillosis and other filamentous fungal infections diagnosed by modified EORTC criteria in immunocompromised patients, as determined by…
- Trial name
- NCT00158730
- Testing
- AmBisome
- Volunteers
- 800 people
- Sponsor
- Gilead Sciences
Infection, Unspecified Adult Solid Tumor, Protocol Specific
Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections
RATIONALE: Antifungals such as voriconazole may be effective in controlling fungal infections. Combining voriconazole with interferon gamma may be more effective than voriconazole alone in treating fungal infections.
- Trial name
- NCT00059878
- Testing
- recombinant interferon gamma, voriconazole
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cerebral Aspergillosis, Invasive Aspergillosis
European Study of Cerebral Aspergillosis Treated With Isavuconazole
Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality.
- Trial name
- ESCAI (NCT04486885)
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Imagine Institute
Invasive Aspergillosis
Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy
Invasive pulmonary aspergillosis (IPA) remains a major cause for morbidity and mortality in patients (pts) with hematologic malignancies.
- Trial name
- NCT01448226
- Where
- 22 sites in Austria, Germany
- Volunteers
- 221 people
- Sponsor
- Heidelberg University